July 30 Company Quick Takes: Gilead beats on revenues with the help of Biktarvy, Yescarta; plus Pfizer and Ligand

Biktarvy, Yescarta beat estimates
Gilead Sciences Inc. (NASDAQ:GILD) raised its 2019 sales guidance after reporting higher-than-expected 2Q19 earnings driven by sales

Read the full 206 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE